Diabetic foot infection: Difference between revisions

From IDWiki
No edit summary
m (Text replacement - " species]]" to "]]")
 
(2 intermediate revisions by the same user not shown)
Line 6: Line 6:
**[[Staphylococcus aureus]], which is by far the most common cause of monomicrobial infections
**[[Staphylococcus aureus]], which is by far the most common cause of monomicrobial infections
**[[Coagulase-negative staphylococci]]
**[[Coagulase-negative staphylococci]]
**[[Streptococcus species]]
**[[Streptococcus]]
**[[ENterococcus species]]
**[[Enterococcus]]
**[[Enterobacteriaceae]]
**[[Enterobacteriaceae]]
**[[Pseudomonas aeruginosa]]
**[[Pseudomonas aeruginosa]]
Line 13: Line 13:
*Anaerobes are more likely to be involved in deeper, more chronic ulcers
*Anaerobes are more likely to be involved in deeper, more chronic ulcers


== Diagnosis ==
==Diagnosis==


* Osteomyelitis should be considered in all cases of diabetic foot infection
*Osteomyelitis should be considered in all cases of diabetic foot infection
** [[Probe-to-bone test]] should be done routinely
**[[Probe-to-bone test]] should be done routinely
** Plain film X-ray can be helpful, though not sensitive
**Plain film X-ray can be helpful, though not sensitive
** MRI is the preferred diagnostic test, followed by bone and white cell scan
**MRI is the preferred diagnostic test, followed by bone and white cell scan
** The gold standard is still bone biopsy for histopathology and culture
**The gold standard is still bone biopsy for histopathology and culture


==Management==
==Management==
Line 29: Line 29:
|-
|-
| rowspan="7" |Mild
| rowspan="7" |Mild
| rowspan="5" |methicillin-susceptible [[Staphylococcus aureus]], [[Streptococcus species]]
| rowspan="5" |methicillin-susceptible [[Staphylococcus aureus]], [[Streptococcus]]
|[[dicloxacillin]]
|[[dicloxacillin]]
|qid dosing and very narrow-spectrum
|qid dosing and very narrow-spectrum
Line 53: Line 53:
|-
|-
| rowspan="13" |moderate or severe
| rowspan="13" |moderate or severe
| rowspan="9" |[[MSSA]], [[Streptococcus species]], [[Enterobacteriaceae]], [[anaerobes]]
| rowspan="9" |[[MSSA]], [[Streptococcus]], [[Enterobacteriaceae]], [[anaerobes]]
|[[levofloxacin]]
|[[levofloxacin]]
|suboptimal against MSSA
|suboptimal against MSSA
Line 96: Line 96:
|}
|}


=== Duration ===
===Duration===
{| class="wikitable"
!Site of Infection
!Severity
!Duration
|-
| rowspan="3" |soft tissue only
|mild
|1 to 2 weeks; up to 4 weeks if slow-to-resolve
|-
|moderate
|1 to 3 weeks
|-
|severe
|2 to 4 weeks
|-
| rowspan="4" |bone and joint infection
|postamputation, with no residual infection
|2 to 5 days
|-
|postamputation, with residual soft tissue infection
|1 to 3 weeks
|-
|postamputation, with residual bone infection
|4 to 6 weeks
|-
|no surgery
|≥3 months
|}


*After amputation or resection
**If good source control, only 2 to 5 days is recommended
**If there is persistent infection or necrotic bone, 4 or more weeks
*Osteomyelitis
*Osteomyelitis
**Traditionally, 6 weeks of parenteral therapy
**Traditionally, 6 weeks of parenteral therapy

Latest revision as of 04:02, 28 January 2022

Background

Microbiology

Diagnosis

  • Osteomyelitis should be considered in all cases of diabetic foot infection
    • Probe-to-bone test should be done routinely
    • Plain film X-ray can be helpful, though not sensitive
    • MRI is the preferred diagnostic test, followed by bone and white cell scan
    • The gold standard is still bone biopsy for histopathology and culture

Management

Severity Common Pathogens Antibiotics Notes
Mild methicillin-susceptible Staphylococcus aureus, Streptococcus dicloxacillin qid dosing and very narrow-spectrum
clindamycin active against MRSA but higher risk of CDAD
cephalexin qid dosing
levofloxacin not as effective against Staphylococcus aureus
amoxicillin-clavulanic acid broad-spectrum, includes anaerobic coverage
methicillin-resistant Staphylococcus aureus doxycycline uncertain activity against streptococci
TMP-SMX uncertain activity against streptococci
moderate or severe MSSA, Streptococcus, Enterobacteriaceae, anaerobes levofloxacin suboptimal against MSSA
cefoxitin
ceftriaxone
ampicillin-sulbactam
moxifloxacin
ertapenem
tigecycline
fluoroquinolone with clindamycin
imipenem-cilastatin
MRSA linezolid
daptomycin
vancomycin
Pseudomonas aeruginosa piperacillin-tazobactam

Duration

Site of Infection Severity Duration
soft tissue only mild 1 to 2 weeks; up to 4 weeks if slow-to-resolve
moderate 1 to 3 weeks
severe 2 to 4 weeks
bone and joint infection postamputation, with no residual infection 2 to 5 days
postamputation, with residual soft tissue infection 1 to 3 weeks
postamputation, with residual bone infection 4 to 6 weeks
no surgery ≥3 months
  • Osteomyelitis
    • Traditionally, 6 weeks of parenteral therapy
    • May be able to shorten to 3 weeks if adequately debrided, based on more recent evidence1

Further Reading

References

  1. ^  Karim Gariani, Truong-Thanh Pham, Benjamin Kressmann, François R Jornayvaz, Giacomo Gastaldi, Dimitrios Stafylakis, Jacques Philippe, Benjamin A Lipsky, İlker Uçkay. Three versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: A prospective, randomized, non-inferiority pilot trial. Clinical Infectious Diseases. 2020. doi:10.1093/cid/ciaa1758.